Scholarlink

<p>Approved mRNA vaccines administered intramuscularly (i.m.) induce strong systemic immune responses, but provide limited protection at the respiratory mucosa, where many infections are initiated. Designing safe and efficacious mucosal vaccines is challenging because it requires vaccine administration at the mucosa that is equipped with protective barriers and characterized by tolerogenic predominance. Here we show that i.m. prime immunization of mice with lipid nanoparticles (LNPs) loaded with mRNA encoding the SARS-CoV-2 spike protein, followed by pulmonary pull immunization with either mRNA-LNPs or spike protein adjuvanted with cationic adjuvant formulation (CAF)01 induce high systemic immune responses and virus-neutralizing spike-specific antibody responses in the lungs. However, only pulmonary pull immunization with CAF01-adjuvanted spike protein induces spike-specific mucosal antibody and lung-resident T-cell responses in the respiratory tract. This suggests that i.m. priming of strong immune responses with mRNA-LNPs combined with mucosal pull immunization with a subunit vaccine can re-direct the immune response to the respiratory mucosa.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Induction of mucosal immune responses against SARS-CoV-2: a heterologous intramuscular mRNA-LNP prime/pulmonary recombinant subunit pull vaccination strategy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Melike Ongun,
  • Naga Suresh Kola,
  • Dhruv Patel,
  • Tasson da Costa Rodrigues,
  • Signe Tandrup Schmidt,
  • Abhijeet Girish Lokras,
  • Henrik Franzyk,
  • Søren R. Paludan,
  • Thomas Rades,
  • Aneesh Thakur,
  • Camilla Foged

摘要

Approved mRNA vaccines administered intramuscularly (i.m.) induce strong systemic immune responses, but provide limited protection at the respiratory mucosa, where many infections are initiated. Designing safe and efficacious mucosal vaccines is challenging because it requires vaccine administration at the mucosa that is equipped with protective barriers and characterized by tolerogenic predominance. Here we show that i.m. prime immunization of mice with lipid nanoparticles (LNPs) loaded with mRNA encoding the SARS-CoV-2 spike protein, followed by pulmonary pull immunization with either mRNA-LNPs or spike protein adjuvanted with cationic adjuvant formulation (CAF)01 induce high systemic immune responses and virus-neutralizing spike-specific antibody responses in the lungs. However, only pulmonary pull immunization with CAF01-adjuvanted spike protein induces spike-specific mucosal antibody and lung-resident T-cell responses in the respiratory tract. This suggests that i.m. priming of strong immune responses with mRNA-LNPs combined with mucosal pull immunization with a subunit vaccine can re-direct the immune response to the respiratory mucosa.